<DOC>
	<DOCNO>NCT00392028</DOCNO>
	<brief_summary>The aim study determine penetration level ertapenem bone tissue patient Diabetes Mellitus ( D.M ) Peripheral Vascular Diseases ( P.V.D ) undergo amputation , correlate theme concentration drug blood soft tissue</brief_summary>
	<brief_title>Penetration Ertapenem Into Bone</brief_title>
	<detailed_description>Twelve patient D.M P.V.D undergo bellow knee amputation without gangrene . Within four week prior amputation vascular profile determine Doppler skin perfusion determine transcutaneous oxygen pressure measurement ( TcPO2 ) dorsal side mid foot affect limb . Each patient receive 1 g Ertapenem 100 ml normal saline IV infusion -during 30 minute IVAC : - -2 day prior amputation - -1 day prior amputation - 1 hour amputation The infusion start approximately time 3rd infusion , prior plan amputation . Blood sample ( approximately 6ml ) collect Ertapenem administration , simultaneously bone soft tissue sample time amputation end surgery</detailed_description>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Age &gt; 18 Diabetes Mellitus Peripheral Vascular Disease Undergoing bellow knee amputation without gangrene Patients without clinical sign acute infection Creatinine Clearence 60 cc/ min Known hypersensitivity component ertapenem drug class . Patients demonstrate anaphylactic reaction betalactams . CNS disorder ( e.g. , brain lesion history seizure ) . Patient treat antibiotic least 72 hour . Pregnant woman , nurse woman , fertile woman practice adequate method contraception . Patient legal representative patient unable provide write informed consent reason . Patient history illness , opinion investigator , might confound result study pose additional risk administer study drug patient . Neutropenia Renal failure Hepatic Insufficiency : &gt; x 2 upper limit . A need additional concomitant systemic antibacterial agent . Life expectancy le 6 month Patient undergo immunosuppressive therapy , include use high dose corticosteroid ( e.g.,20 mg prednisone equivalent per day ) Patient situation condition , investigator 's opinion , may interfere optimal participation study . Participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Ertapenem</keyword>
	<keyword>Bone drug level</keyword>
	<keyword>Blood drug level</keyword>
	<keyword>Tissue drug level</keyword>
</DOC>